Cipla Limited Earnings Summary — Q1 FY2027
Cipla Reports Q1 FY27 Results Amid Revenue Reclassification and Margin Pressure
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue grew 8.8% sequentially in Q1 FY2027.
- Revenue of ₹7,119 Cr is 2.3% higher year-on-year.
- Revenue has compounded at 6.6% annualised over the last 10 quarters.
- Net profit of ₹789 Cr is 39.2% below the same quarter last year.
- Profit growth is trailing revenue growth this quarter.
- Net profit has compounded at -7.4% annualised across the period.
- Operating margin stands at 16.8% in Q1 FY2027.
- Operating margin compressed by 881 bps year-on-year.
- Over the last two years operating margin has contracted by 888 bps.
- PBT margin is 15.2%.
- Expenses grew 14.4% against revenue growth of 2.3%.
- Operating profit of ₹1,192 Cr is 32.9% lower year-on-year.
- Operating leverage has been under pressure recently.
- 4 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 49/100 (Moderate) on the latest 10 quarters.
- Business momentum has softened and warrants monitoring.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Stable | 7,119 | 6,541 | 7,074 | 7,589 | 6,957 | 6,730 | 7,073 | 7,051 | 6,694 | 6,163 |
| Expenses | Stable | 5,927 | 5,586 | 5,819 | 5,695 | 5,179 | 5,192 | 5,084 | 5,165 | 4,978 | 4,847 |
| Operating Profit | Stable | 1,192 | 955 | 1,255 | 1,895 | 1,778 | 1,538 | 1,989 | 1,886 | 1,716 | 1,316 |
| Operating Margin | Stable | 16.8% | 14.6% | 17.7% | 25.0% | 25.6% | 22.9% | 28.1% | 26.7% | 25.6% | 21.4% |
| Other Income | Volatile | 211 | 148 | -70 | 269 | 259 | 289 | 222 | 191 | 160 | 249 |
| Interest | Accelerating | 17 | 13 | 14 | 13 | 14 | 14 | 15 | 15 | 18 | 18 |
| Depreciation | Stable | 304 | 383 | 278 | 297 | 253 | 309 | 280 | 272 | 247 | 288 |
| Profit Before Tax | Improving | 1,082 | 707 | 893 | 1,854 | 1,770 | 1,504 | 1,916 | 1,789 | 1,611 | 1,259 |
| Tax | Volatile | 295 | 157 | 219 | 500 | 478 | 279 | 332 | 483 | 435 | 325 |
| Net Profit | Stable | 789 | 555 | 676 | 1,351 | 1,298 | 1,222 | 1,571 | 1,303 | 1,178 | 939 |
| Net Margin | Stable | 11.1% | 8.5% | 9.6% | 17.8% | 18.6% | 18.2% | 22.2% | 18.5% | 17.6% | 15.2% |
Key Takeaways
- Revenue grew by 2.3% YoY to ₹7,119.28 Crores, showing resilience despite a change in accounting for marketing expenses.
- Net profit fell significantly by 39% YoY to ₹785.55 Crores, though it recovered 44.8% on a sequential basis.
- Effective April 1, 2026, Cipla changed its accounting policy to present certain marketing expenditures as a reduction from revenue rather than as other expenses.
- The company faces a significant contingent liability of ₹2,011 Crores related to ongoing DPCO overcharge litigations with the NPPA.
- Operating segments were consolidated following a change in the Chief Operating Decision Maker (CODM); Cipla now operates as a single 'Pharmaceutical' segment.
- The company continues to pursue the amalgamation of its wholly owned subsidiary, Inzpera Healthsciences Limited.
- Inventory costs saw a notable shift, with a net increase in inventories of ₹58.55 Crores compared to subtractions in prior periods.
- Employee benefits rose to ₹1,497 Crores, reflecting a steady increase in human capital costs.
Management Guidance
Management has transitioned the company toward high-complexity generics and respiratory products to ensure sustainable competitive advantages. They continue to monitor the implementation of the 'New Labour Codes' which necessitated prior exceptional items.
Sentiment Shift
Stable
While YoY profits are down sharply due to a high base and cost pressures, sequential improvement suggests stabilization in core operations.
Outlook
The outlook remains focused on quality-by-design and scaling the US generics business through respiratory inhalers. However, regulatory headwinds and pricing pressure in the US generic market remain key monitoring points.
From the Annual Report (Key Quotes)
“Effective 1st April, 2026, the Group presents certain marketing and promotional expenditures as a reduction from Revenue from Operations.”
“The Company has been legally advised that it expects a favourable outcome in respect of these [DPCO] matters and therefore no provision is considered necessary.”
“Group has determined that it operates as a single operating segment, namely Pharmaceutical and related products.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Cipla Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.